Marc Blaustein
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Marc Blaustein
Earlier roles on record: COO at Finch Therapeutics Group, Inc. (FNCHQ) until May 15, 2023. Finch Therapeutics Group, Inc. reported in an 8-K filed April 25, 2023 that Marc Blaustein was terminated as Chief Operating Officer, effective May 15, 2023. The proxy statement of Finch Therapeutics Group, Inc. reports total compensation of $816,544 for Marc Blaustein in fiscal 2022, including a base salary of $415,000. Disclosed compensation is on record for 2 fiscal years.
“On April 21, 2023, the Board of Directors (the “Board”) of Finch Therapeutics Group, Inc. (the “Company”) approved the termination of employment, without cause, of each of Mark Smith, Ph.D., and Marc Blaustein, the Company’s Chief Executive Officer and Chief Operating Officer, in each case effective May 15, 2023.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Start not stated–2023-05-15
Company network
Recorded roles and call appearances connecting this person to public companies.
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2022 | Finch Therapeutics Group, Inc. (FNCHQ) | Chief Operating Officer | $415,000 | $816,544 |
| 2021 | Finch Therapeutics Group, Inc. (FNCHQ) | Chief Operating Officer | $112,308 | $1,851,590 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.